March 5, 2014
Baxam Law Group, LLC, a law firm based in Duluth, Georgia, today announced the settlement of a trademark dispute that was initiated in the United States Patent and Trademark Office (USPTO) over the firm’s application for registration of its service mark, LAW FOR TODAY’S BUSINESS. The opposition (a dispute proceeding in the USPTO) was filed by Howard & Howard, PLLC, a Michigan-based law firm. Today’s agreement resolves all disputes between the two firms and allows each firm to continue using and to register its respective marks without interference from the other.
Howard & Howard’s opposition alleged that registering Baxam Law’s mark would lead to a likelihood of confusion in the marketplace and dilution of Howard & Howard’s own trademark registrations, which included the phrase LAW FOR BUSINESS. Baxam Law counterclaimed that the phrase LAW FOR BUSINESS is generic and therefore its registration by Howard & Howard as a service mark in the USPTO should be canceled.
According to Baxam Law’s principal, Deanna Baxam, “This settlement vindicates our uninhibited right to use LAW FOR TODAY’S BUSINESS as a unique identifier for our fresh, contemporary model of client-focused, high quality and value-conscious services. We’re a twenty-first century law firm.”
Baxam Law specializes in providing intellectual property, healthcare and related legal services to corporations, research organizations and entrepreneurs.
Find Baxam Law on Facebook and Twitter.
Posted in Uncategorized
Tagged atlanta, baxam law, Business, compliance, copyright, corporate, deanna baxam, dispute, entertainment, federal, genericness, healthcare, Intellectual property, law firm, lawyer, likelihood of confusion, litigation, medical device, opposition, patent, Patent & Trademark Office, service mark, settlement, trademark, trademark dilution, USPTO
Of the 18 new drug and biologics molecules approved in 2010, about half seemed to have been developed by small companies. The Center for Drug Evaluation and Research (CDER) just announced an upcoming forum on designing clinical trials. This session is specifically for small businesses who want to learn more about how to plan and execute trials so they will generate data that meets FDA‘s review standards.
The meeting will be held on April 21, 2011 from 9:00 a.m. to 4:45 p.m. at the FDA White Oak Campus in Silver Spring, MD, just outside Washington, D.C.
According to CDER, topics to be covered include:
– Clinical trial design – the phased approach and the staged approach
– FDA’s Bioresearch Monitoring (BIMO) Inspection Program
– Challenges to conducting clinical research in the 21st century
– Practical concerns of electronic source documentation
– Different types of pharmacokinetic studies conducted during drug development
– Importance of bioequivalence studies
– Strategic Quality for Clinical Trials
– FDA inspection process
There is no fee to register for this meeting, and there are limited seats available.
Register, and download the agenda and presentation slides here.
Baxam Law Group, LLC advises startups and small business clients in intellectual property, regulatory and commercial law.
Posted in Regulatory Law
Tagged big pharma, Biotechnology and Pharmaceuticals, Business, Center for Drug Evaluation and Research, Clinical trial, Drug development, FDA, Food & Drug Administration, new drug, new drugs, Pharmaceuticals, R&D, research and development, small pharma, supplements